News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
73–82
Matches
82
Sources here
1
Companies here
1
Search results Stored financial headlines

Active search

82 matching headlines

Ticker or company: N1VO34Main company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Weight-loss wars: Why Novo Nordisk is suing Eli Lilly

Novo Nordisk (NVO) is suing Eli Lilly (LLY) for misleading advertising. Morning Brief host Julie Hyman discusses the details with Yahoo Finance Breaking Business News Reporter Jake Conley and Payne Capital Management president Ryan Payne. Video Transcript 00:00 Speaker A Novo Nordisk is filing …

N1VO34 main company
Sharemaestro market context Trend signal started 52 weeks -21.7% · Next-week setup positive 57.2% N1VO34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move

Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled. Continue Reading

N1VO34 main company
Sharemaestro market context Trend signal started 52 weeks -21.7% · Next-week setup positive 57.2% N1VO34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have …

N1VO34 main company
Sharemaestro market context Trend signal started 52 weeks -21.7% · Next-week setup positive 57.2% N1VO34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Pharma heavyweights clash over anti-obesity drug ads

Anti-obesity treatments have been a financial windfall for Novo Nordisk and Eli Lily (SEBASTIEN BOZON) Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over "false and materially misleading" adverts for their competing weight-loss and anti-diabetes treatments. …

N1VO34 main company
Sharemaestro market context Trend signal started 52 weeks -21.7% · Next-week setup positive 57.2% N1VO34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom. Novo Nordisk Inc. filed a lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly and Company and …

N1VO34 main company
Sharemaestro market context Trend signal started 52 weeks -21.7% · Next-week setup positive 57.2% N1VO34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Novo Nordisk (CPSE:NOVO B) Launches Kyinsu In China Through Fangzhou Internet Hospital

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Novo Nordisk (CPSE:NOVO B) and Fangzhou have launched Kyinsu®, the world's first once weekly basal insulin/GLP-1 RA combination therapy, in China. The product is being introduced through …

N1VO34 main company
Sharemaestro market context Trend signal started 52 weeks -21.7% · Next-week setup positive 57.2% N1VO34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Does EU Approval of Wegovy Pill Change NVO's Competitive Story?

Novo Nordisk NVO received a meaningful commercial boost last week after the European Commission approved the oral version of Wegovy (semaglutide 25 mg) for adults with obesity and at least one weight-related comorbidity. The approval expands the company's obesity franchise across Europe, making Wegovy …

N1VO34 main company
Sharemaestro market context Trend signal started 52 weeks -21.7% · Next-week setup positive 57.2% N1VO34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

July 2026 CHMP meeting commences today, prior to FDA inspection classification for Catalent Indiana LLC (part of Novo Nordisk) fill-finish facility Apitegromab CHMP Opinion expected following resolution of Catalent Indiana classification status or inclusion of second fill-finish facility in MAA CAMBRIDGE, Mass., July 20, …

N1VO34 main company
Sharemaestro market context Trend signal started 52 weeks -21.7% · Next-week setup positive 57.2% N1VO34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China

Fangzhou Inc. SHANGHAI, July 20, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, announced the launch of Kyinsu®, the world's first once-weekly basal insulin/GLP-1 RA combination therapy, on its Internet hospital platform, …

N1VO34 main company
Sharemaestro market context Trend signal started 52 weeks -21.7% · Next-week setup positive 57.2% N1VO34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Wegovy Pill in Europe - Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The European Commission approved Novo Nordisk A/S' Wegovy pill, a once-daily oral semaglutide 25 mg treatment for adults with obesity or overweight with at least one weight-related …

N1VO34 main company
Sharemaestro market context Trend signal started 52 weeks -21.7% · Next-week setup positive 57.2% N1VO34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context